Circulating Tumour Protein Quantification From Capillary Blood for Patient Selfsampling and Safe Remote Monitoring of Multiple Myeloma During COVID-19
Sponsor study identifier
observational
70
1 country
1
Study Start
March 4, 2021
Actual (reported)Primary Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The coronavirus (COVID-19) pandemic has brought severe challenges for myeloma patients. Myeloma patients are considered ultra-high risk for COVID-19 and fall into the strictest group for shielding. When on treatment, but also during times of active surveillance, patients have to regularly and frequently leave shielding and visit the hospital for blood tests to monitor their disese. This is specifically for quantification of circulating tumour protein biomarker tests for paraprotein (PP) and/or serum free light chains (sFLCs) by specialised biochemistry units. This research aims to evaluate the potential use of an at-home patient administered technique to sample blood. The purpose of the blood sampling technique is to monitor your disease status. We want to test if it is possible to monitor a patient's disease status using this alternative blood collection method when compared to monitoring disease status using the traditional blood collection methods (venous blood sampling). The new VAMS method is not intended to be used interchangeably or will not replace the current method. This study is to evaluate an alternative sample type that may be used to improve the patient pathway, especially during these uncertain times.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 8, 2020
Actual (reported)December 9, 2020
Actual (reported)March 4, 2021
Actual (reported)December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Validated FLC
Validated FLC method for use with VAMS that conforms to ISO15189:2012 accreditation
6 months
This is a non-interventional study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Multiple myeloma patients attending routine phlebotomy clinic.
The Royal Marsden NHS Foundation Trust
Sutton, SM25PT, United Kingdom
Kevin Boyd
Royal Marsden NHS Foundation Trust
First Submitted
December 8, 2020
First Posted
December 9, 2020
Study Start
March 4, 2021
Actual (reported)Primary Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Contact the study team to confirm eligibility.
Study Completion
December 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 11, 2021
Record last verified: 2021-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: